|
In an exclusive interview with S&P Global Market Intelligence, Dana-Farber Cancer Institute Inc. President and CEO Laurie Glimcher said the unique culture at the nonprofit research and treatment center allows for seamless collaboration, which is how breakthroughs are made.
Collaboration with biotechnology and pharmaceutical companies in the private sector is also critical: "We're very eager to work with the private sector because it's better for our patients and things just get done faster in a commercial setting," Glimcher said.
"Our mission is always, how do we get our basic research discoveries into patients as fast as we can?"
Glimcher also discussed new horizons in cancer research and targets that could someday improve the lives of patients, but there is still work to be done, she said. To achieve these goals, Dana-Farber is diving into the world of artificial intelligence and data sharing to understand the different kinds of cancer and the unique genetic makeup of each patient — matching data points with outcomes to ensure the right patient gets on the right drug.
"This is my dream, that within a few years we will be able to do this if we utilize the latest technologies, which we are doing at Dana-Farber," Dr. Glimcher said.
Dana-Farber CEO: Collaboration is essential for next cancer breakthrough
Chart of the week

ESMO 2019: Ovarian cancer is center stage as focus shifts to targeted therapies
Must read
Amgen's rise in biosimilar space may signal turning tide for US market
Amgen Inc. and other biosimilar makers are seeing a change in the U.S. market and are beginning to benefit from their early work in the space, despite years of developmental, regulatory and legal setbacks.
|
First In Human: Cannabis research ramps up in opioid replacement, neuroscience
In this month's column, researchers delve into the murky, strictly regulated field of medical cannabis, parsing out the complex substance's potential therapeutic abilities and effects on pain, essential tremor and bipolar disorder.
House report backs up Pelosi's push to use foreign pricing for US medicines
A report by the U.S. House Ways and Means Committee found that American consumers pay on average nearly four times more for drugs than what is paid in certain countries — and in some cases, 67 times more for the same medicine.
Tennessee's test of Medicaid block grant could cross a regulatory red line
As Tennessee attempts to become the first state to have a Medicaid block grant waiver approved by the Trump administration, legal experts expect the proposal to become locked up in court before it is ever implemented.
Mallinckrodt braces for legal settlements amid pursuit of new medicines
Mallinckrodt PLC, the 150-year-old drug company whose stock has fallen more than 90% in the last year, is bracing for the worst as it faces two legal threats involving its products.

In other news
Trump health official calls site-neutral Medicaid ruling a 'setback'
A top Trump administration health official said a federal court decision that dealt a blow to efforts to establish site-neutral Medicare payments is a cautionary tale of too much government control in the U.S. healthcare system.
|
Lawmakers wrangle over Pelosi drug pricing bill; Grassley measure may wait
The Democratic head of the House Energy and Commerce Health Subcommittee vowed to take Speaker Nancy Pelosi's drug pricing bill through the regular order legislative process, while a Senate bill may wait until early next year to be considered.
China selects 7 international drugmakers under expanded purchase program
Sanofi, Eli Lilly and Co., AstraZeneca PLC, Merck & Co. Inc. and Dr. Reddy's Laboratories Ltd. are among the international companies selected, according to a notice posted on a Shanghai city government website.
Novo Nordisk to price oral diabetes drug Rybelsus similar to injectable Ozempic
The Danish drugmaker plans to price Rybelsus, the newly approved oral version of its diabetes therapy semaglutide, similarly to the injectable version of the drug, executives said in a Sept. 23 call with analysts.
Capitol Checkup: Clash expected at House drug pricing hearing; US FDA reaches for 'the cloud'
House Democrats and Republicans will get their first chance to debate Speaker Nancy Pelosi's drug pricing package at a Sept. 25 hearing, where three other bills will also be vetted, and U.S. drug regulators unveiled a technology modernization plan.
Essential Healthcare is a weekly collection of critical developments across the pharmaceutical, biotechnology, healthcare provider, healthcare technology and medical equipment industries that draws on exclusive analysis and value-added content from the Healthcare News team at S&P Global Market Intelligence. Subscribe now to get Essential Healthcare delivered to your inbox every week.

Dana-Farber Cancer Institute Inc. President and CEO Laurie Glimcher
Rep. Anna Eshoo, D-Calif., chair of the House Energy and Commerce Health Subcommittee, promised Republicans during a Sept. 25 hearing that they would have plenty of opportunity to suggest changes to a drug pricing bill proposed by House Speaker Nancy Pelosi.